

AXIM BIOTECH TO PRESENT RESEARCH ABSTRACTS AT THE 6TH PHARMACEUTICAL WORLD CONGRESS

NEW YORK – May 23, 2017 – AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that Lekhram Changoer, Chief Technology Officer will present company's research at the upcoming 6th Pharmaceutical Sciences World Congress (PSWC), to be held from May 21-24, 2017 in Stockholm, Sweden.

Mr. Changoer will present under the program track on Drug Delivery & Targeting Sciences on the following two topics:

- 1) Chewing Gum; a Novel Delivery System for Hemp oil-derived Cannabidiol (CBD) Formulations in the Treatment of Irritable Bowel Syndrome (IBS) Patients
and
- 2) Chewing Gum; a Novel Delivery System for Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Formulations for the Treatment of Pain and Spasticity in Multiple Sclerosis (MS) Patients

Organized by International Pharmaceutical Federation (FIP), PSWC is a leading global forum where scientists meet and network with key leaders from the pharmaceutical industry, government agencies, regulatory bodies, academia and public-private partnerships.

###

About AXIM®

AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact:

Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:

Shiwei Yin, Grayling
Shiwei.Yin@grayling.com
P. +1646 284-9474
Lucia Domville, Grayling
lucia.domville@grayling.com
P. +1646 284-9416

Corporate Contact Info:

North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:

Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227